An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies

被引:18
|
作者
Fleseriu, Maria [1 ,2 ,3 ]
Fogelfeld, Leon [4 ]
Gordon, Murray B. [5 ]
Sisco, Jill [6 ]
Crosby, Ross D. [7 ,8 ,9 ]
Ludlam, William H. [10 ]
Haviv, Asi [10 ]
Mathias, Susan D. [7 ]
机构
[1] Oregon Hlth & Sci Univ, Dept Med, 3303 SW Bond Ave,CH8N, Portland, OR 97239 USA
[2] Oregon Hlth & Sci Univ, Dept Neurol Surg, 3303 SW Bond Ave,CH8N, Portland, OR 97239 USA
[3] Oregon Hlth & Sci Univ, Northwest Pituitary Ctr, 3303 SW Bond Ave,CH8N, Portland, OR 97239 USA
[4] Rush Univ, Med Ctr, John H Stroger Jr Hosp Cook Cty, Chicago, IL 60612 USA
[5] Allegheny Gen Hosp, Allegheny Neuroendocrinol Ctr, Pittsburgh, PA 15212 USA
[6] Acromegaly Community, Grove, OK USA
[7] Hlth Outcomes Solut, Winter Pk, FL USA
[8] Neuropsychiat Res Inst, Fargo, ND USA
[9] Univ North Dakota, Sch Med & Hlth Sci, Fargo, ND USA
[10] Chiasma Inc, Waltham, MA USA
关键词
Acromegaly; Patient reported outcomes; Quality of life; Acro-TSQ; Validation; Measurement properties; Questionnaire; QUALITY-OF-LIFE;
D O I
10.1007/s11102-020-01038-y
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose The Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) is a new patient-reported outcome (PRO) measure for patients with acromegaly receiving injectable somatostatin analogs (SSAs) to assess clinical symptoms and adverse drug reaction interference, treatment satisfaction, and convenience. We evaluated its scale structure, reliability, validity, responsiveness, and what constitutes clinically meaningful change. Methods Data from two longitudinal studies (N = 79 and 82) of patients receiving a stable injectable SSA dose for >= 6 months who completed the Acro-TSQ and other collateral measures (e.g., AcroQoL, AIS, WPAI:SHP, EQ-5D-5L) were analyzed. Results The first study demonstrated internal consistency of the Acro-TSQ. However, several items had high ceiling effects, responsiveness could not be established, and the minimally important difference (MID) was not estimable. In the second study, factor analysis revealed six scales: Symptom Interference, Treatment Convenience, Injection Site Interference, GI Interference, Treatment Satisfaction, and Emotional Reaction. Internal consistency and test-retest reliability were confirmed; most scales demonstrated significant differences in mean scores by disease severity. Correlations between Acro-TSQ scales and other collateral measures exceeded 0.30 in absolute value, confirming convergent validity. Responsiveness in Acro-TSQ scale scores reflected improved disease control. The MID was estimated for Symptom Interference (10-12 points), Treatment Convenience (9-11) and GI Interference (8-10). Conclusions The Acro-TSQ is a brief, yet comprehensive tool to monitor important outcomes associated with injectable acromegaly SSA treatments. Its content reflects both disease and treatment burden as well as patient satisfaction, and its relevant for use in clinical studies.
引用
收藏
页码:347 / 358
页数:12
相关论文
共 4 条
  • [1] An evaluation of the Acromegaly Treatment Satisfaction Questionnaire (Acro-TSQ) in adult patients with acromegaly, including correlations with other patient-reported outcome measures: data from two large multicenter international studies
    Maria Fleseriu
    Leon Fogelfeld
    Murray B. Gordon
    Jill Sisco
    Ross D. Crosby
    William H. Ludlam
    Asi Haviv
    Susan D. Mathias
    [J]. Pituitary, 2020, 23 : 347 - 358
  • [2] Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)
    Andrew Blauvelt
    Craig L. Leonardi
    Norman Gaylis
    Julia Jauch-Lembach
    Alison Balfour
    Lena Lemke
    Sohaib Hachaichi
    Ines Brueckmann
    Teodora Festini
    Piotr Wiland
    [J]. BioDrugs, 2021, 35 : 229 - 238
  • [3] Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS)
    Blauvelt, Andrew
    Leonardi, Craig L.
    Gaylis, Norman
    Jauch-Lembach, Julia
    Balfour, Alison
    Lemke, Lena
    Hachaichi, Sohaib
    Brueckmann, Ines
    Festini, Teodora
    Wiland, Piotr
    [J]. BIODRUGS, 2021, 35 (02) : 229 - 238
  • [4] EVALUATION OF INTERNAL CONSISTENCY, FEASIBILITY, AND RELIABILITY OF THE ITALIAN VERSION OF ANCA-ASSOCIATED VASCULITIS PATIENT-REPORTED OUTCOME (AAV-PRO_ITA) QUESTIONNAIRE: PRELIMINARY RESULTS FROM A MULTICENTER STUDY ON A LARGE COHORT OF ITALIAN PATIENTS
    Treppo, E.
    Isola, M.
    De Martino, M.
    Padoan, R.
    Urban, M. L.
    Monti, S.
    Sartorelli, S.
    Giollo, A.
    Argolini, L. M.
    Marvisi, C.
    Ferro, F.
    Cassone, G.
    Motta, F.
    Berti, A.
    Conticini, E.
    Manfredi, A.
    Frediani, B.
    Bortolotti, R.
    Selmi, C.
    Baldini, C.
    Emmi, G.
    Caporali, R.
    Rossini, M.
    Dagna, L.
    Montecucco, C.
    Schiavon, F.
    Salvarani, C.
    De Vita, S.
    Quartuccio, L.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1440 - 1440